🧠 Food for thought

Implications, context, and why it matters.

Previous attempts to clear amyloid deposits after formation have failed in late-stage trials

• Protego focuses on prevention while efforts fell short, as AstraZeneca’s anselamimab missed its primary endpoint in Phase 3 and Prothena stopped birtamimab after no benefit on time to all-cause mortality versus placebo 1.
• These misses make clearing formed deposits hard and support a plan to stabilize proteins before buildup 2.
• Prothena’s NEOD001 posted cardiac and renal responses in Phase 1/2 with biomarker gains 3, yet it failed to extend survival in pivotal testing 1.
• PROT-001 uses a mechanism called a “sharper knife” not a “sledgehammer” to steady immunoglobulin light chains (antibody building blocks that can misfold in this disease) and prevent amyloid buildup instead of trying to clear deposits 2.

Tech-enabled patient recruitment platforms can accelerate enrollment at specialized amyloid light-chain (AL) amyloidosis centers

• Biotech investors and Contract Research Organization (CRO) operators can use the pivotal trial (a registrational study intended to support regulatory approval) to bring patient-finding and remote monitoring to few AL amyloidosis centers.
• Hubs include Washington University’s Amyloid Center of Excellence, Cleveland Clinic, Mayo Clinic (over 3,200 amyloidosis patients annually 4), plus Brigham and Women’s Hospital 567.
• Diagnosis needs Congo red staining (a dye-based test that highlights amyloid under polarized light) plus mass spectrometry (a laboratory technique that identifies proteins by their mass) 5. Recruitment tools that target centers and patient registries could shorten timelines.
• Cardiac plus renal biomarkers anchor endpoints, for example 57% cardiac, 60% renal responses in a Phase 1/2 study 3.